PLX R18

Drug Profile

PLX R18

Alternative Names: PLX R 18; PLX RAD

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Fukushima Medical University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Aplastic anaemia; Graft-versus-host disease
  • Preclinical Acute radiation syndrome

Most Recent Events

  • 27 Feb 2018 Pharmacodynamics data from a preclinical trial in Graft-versus-host disease released by Pluristem
  • 26 Oct 2017 Israel Ministry of Health approves IND application for PLX R18 in Graft versus host disease
  • 23 Oct 2017 Pluristem Therapeutics has patent protection for PLX R18 in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top